Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT04500665
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Kidney Diseases

Eligibility Criteria

Sex
ALL
Age
21 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Colchicine — DRUG
    Colchicine
  • Placebo — DRUG
    Placebo

Study Details

This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

Key Dates

Start date
Nov 1, 2021
Status verified
Sep 2025
Primary completion
Jul 31, 2026
Completion
Nov 11, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Colchicine
    Colchicine 0.3 mg once daily
  • Placebo Comparator: Placebo
    Placebo once daily

Primary Outcome Measure

Between-group change in left ventricular global longitudinal strain [ Time Frame: 4 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115
Leo Buckley, PharmD
[email protected]
617-732-4497

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MA

Related Studies